GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Net Margin %
中文

WuXi Biologics (Cayman) (FRA:1FW2) Net Margin % : 26.69% (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. WuXi Biologics (Cayman)'s Net Income for the six months ended in Jun. 2023 was €292 Mil. WuXi Biologics (Cayman)'s Revenue for the six months ended in Jun. 2023 was €1,095 Mil. Therefore, WuXi Biologics (Cayman)'s net margin for the quarter that ended in Jun. 2023 was 26.69%.

The historical rank and industry rank for WuXi Biologics (Cayman)'s Net Margin % or its related term are showing as below:

FRA:1FW2' s Net Margin % Range Over the Past 10 Years
Min: 7.99   Med: 24.88   Max: 32.93
Current: 19.96


FRA:1FW2's Net Margin % is ranked better than
88.79% of 1026 companies
in the Biotechnology industry
Industry Median: -163.08 vs FRA:1FW2: 19.96

WuXi Biologics (Cayman) Net Margin % Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Net Margin % Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.45 30.09 32.93 28.95 19.96

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.28 35.18 23.38 26.69 13.26

Competitive Comparison of WuXi Biologics (Cayman)'s Net Margin %

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Net Margin % distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Net Margin % falls into.



WuXi Biologics (Cayman) Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

WuXi Biologics (Cayman)'s Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=598.527/2067.446
=28.95 %

WuXi Biologics (Cayman)'s Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin=Net Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=292.141/1094.501
=26.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (FRA:1FW2) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


WuXi Biologics (Cayman) Net Margin % Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines